Ftse Mib
34.396,01
0,06%
DAX
18.518,03
-0,44%
S&P 500
5.652,16
0,37%
NASDAQ
18.466,03
-0,04%
Bitcoin
65.154,03
0,47%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Sanofi (SAN) Sanofi (SAN) Notizie

SAN

Sanofi (SAN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:SAN
DataOraFonteTitoloSimboloCompagnia
09/03/202207:47Dow Jones NewsSanofi Says New Hemophilia Drug Met Primary, Secondary Endpoints in StudyEU:SANSanofi
09/03/202207:00GlobeNewswire Inc.L’étude pivot consacrée à l’efanesoctocog alpha a atteint son critère d’évaluation primaire et ses principaux critères secondaires dans le traitement de l’hémophilie A, illustrant sa supériorité sur une prophylaxie antérieure par facteurEU:SANSanofi
09/03/202207:00GlobeNewswire Inc.Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatmentEU:SANSanofi
08/03/202214:25GlobeNewswire Inc.Sanofi recognized by S&P as one of the most sustainability-committed companiesEU:SANSanofi
08/03/202214:25GlobeNewswire Inc.Sanofi reconnue par S&P parmi les entreprises les plus engagées en faveur du développement durableEU:SANSanofi
07/03/202219:37Dow Jones NewsSanofi to Invest Around EUR1.43 Billion in France Over Next Five YearsEU:SANSanofi
03/03/202208:00GlobeNewswire Inc.Nirsevimab significantly protected infants against RSV disease in Phase 3 trialEU:SANSanofi
03/03/202208:00GlobeNewswire Inc.Le nirsevimab protège significativement les nourrissons contre les infections à VRS selon un essai de phase IIIEU:SANSanofi
02/03/202212:45Dow Jones NewsAdagene in Antibody Licensing Agreement With SanofiEU:SANSanofi
01/03/202213:55Dow Jones NewsDarioHealth in $30 Million Strategic Agreement With Sanofi U.S.EU:SANSanofi
28/02/202211:07Dow Jones NewsECHO BOURSE: Stifel débute le suivi de Sanofi à "acheter" avec un objectif de 120 eurosEU:SANSanofi
28/02/202208:10Dow Jones NewsSanofi: des résultats confortent les profils de tolérance et de sécurité du DupixentEU:SANSanofi
26/02/202218:05GlobeNewswire Inc.Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitisEU:SANSanofi
26/02/202218:05GlobeNewswire Inc.Des données de phase III de dernière minute présentées au Congrès annuel de l’AAAAI 2022 montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes de l’œsophagite à éosinophilesEU:SANSanofi
26/02/202218:00GlobeNewswire Inc.Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticariaEU:SANSanofi
26/02/202218:00GlobeNewswire Inc.Des données de phase III de dernière minute présentées au Congrès annuel de l’AAAAI 2022 montrent que Dupixent® (dupilumab) diminue significativement les démangeaisons et l’urticaire des patients souffrant d’urticaire chronique spontanéeEU:SANSanofi
23/02/202220:16GlobeNewswire Inc.Dépôt du Document d’Enregistrement Universel 2021, contenant le Rapport Financier Annuel, et du « Form 20-F » américainEU:SANSanofi
23/02/202220:16GlobeNewswire Inc.Filing of the 2021 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial ReportEU:SANSanofi
23/02/202212:09Dow Jones NewsSanofi, GSK to Seek Approval for Covid-19 Vaccine After Positive Trial ResultsEU:SANSanofi
23/02/202212:05Dow Jones NewsCovid: Sanofi et GSK vont demander l'approbation de leur vaccin aux autorités de santéEU:SANSanofi
23/02/202211:19GlobeNewswire Inc.Sanofi and GSK to seek regulatory authorization for COVID-19 vaccineEU:SANSanofi
23/02/202211:19GlobeNewswire Inc.Sanofi et GSK vont demander l’approbation réglementaire de leur vaccin contre la COVID-19EU:SANSanofi
22/02/202219:14GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - JANVIER 2022EU:SANSanofi
22/02/202219:14GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - January 2022EU:SANSanofi
22/02/202218:32GlobeNewswire Inc.Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent DirectorsEU:SANSanofi
22/02/202218:32GlobeNewswire Inc.Le Conseil d’administration de Sanofi propose la nomination de Carole Ferrand, Emile Voest et Antoine Yver en qualité d’administrateurs indépendantsEU:SANSanofi
18/02/202209:03Dow Jones NewsSanofi to Scrap Phase 3 Trial for Dupixent in Chronic Spontaneous Urticaria PatientsEU:SANSanofi
18/02/202208:13Dow Jones NewsSanofi arrête un essai évaluant le Dupixent pour traiter l'urticaire chronique spontanéeEU:SANSanofi
18/02/202207:00GlobeNewswire Inc.Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 programEU:SANSanofi
18/02/202207:00GlobeNewswire Inc.Point d’actualité sur le programme de phase III relatif à Dupixent® (dupilumab) dans le traitement de l’urticaire chronique spontanéeEU:SANSanofi
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:SAN

La tua Cronologia

BIT
F22555
Vontobel Financial Produ...
AQSE
ORA
Ora Technology
LSE
HVO
Hvivo
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network